Search

Displaying results 1811 - 1820 of 6198 in total
  1. Drug

    Human vaccinia virus immune globulin

    go.drugbank.com/drugs/DB14112
    ApprovedInvestigational

    The IgG fraction is purified by the anion-exchange column chromatography method and the solution is solvent/detergent-treated to sterilize the compound [A33814]. … Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with

  2. Drug

    Fecal microbiota

    go.drugbank.com/drugs/DB17743
    ApprovedInvestigational

    [A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022. … given an antibacterial treatment for recurrent CDI.

  3. Drug

    Necitumumab

    go.drugbank.com/drugs/DB09559
    ApprovedInvestigationalWithdrawn

    Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. … It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression

  4. Drug

    Danazol

    go.drugbank.com/drugs/DB01406
    ApprovedInvestigational

    A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins.

  5. Drug

    Oxybuprocaine

    go.drugbank.com/drugs/DB00892
    ApprovedInvestigational

    Oxybuprocaine (also known as Benoxinate) is a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its perm...

  6. Drug

    Mitomycin

    go.drugbank.com/drugs/DB00305
    ApprovedInvestigational

    Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_. … [L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix.

  7. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    Delamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan). … Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall [A31965].

  8. Drug

    Soybean oil

    go.drugbank.com/drugs/DB09422
    ApprovedInvestigational

    Derived from soybeans, soybean oil is a common vegetable oil and a source of polyunsaturated and saturated fatty acids. It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsatura...

  9. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.

  10. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT<sub>1</sub>R antagonist, and biphenylsulfonamide, an ET<sub … [L45300,L45315] In September 2024, it was granted full approval for an expanded indication.